1. Medtech Insight
  2. >>Business
  3. >>R&D
  4. >>Clinical Trials

Research In Brief

Data updates from HRS, SCAI meetings, and more.

A percutaneous coronary intervention procedure was successfully completed using the CorPath 200 remote robotic system in 98.8% of patients in the 164-patient PRECISE trial without converting to manual PCI and without device-related complications, researchers reported May 10 at the Society for Cardiovascular Angiography and Interventions annual meeting in Las Vegas. The trial is intended to support sponsor Corindus Vascular Robotics’ 510(k) submission for a PCI indication for the system. (See Also see "Robotics: Corindus, Hansen Pursue Vascular Cath Lab Indications" - Medtech Insight, 14 March, 2011..) CorPath 200 allows an interventional cardiologist to control robotic instruments to perform angioplasty and stent placement with a joystick from a radiation-protected “cockpit” without the need for a lead apron. Overall procedure success in the trial was 97.6%, and physician exposure to radiation was reduced by 95.2%.

Investigators reported success in a small study treating coronary disease patients with a robotically assisted procedure combining coronary artery bypass surgery and percutaneous coronary intervention May 10 at the SCAI...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 
• By Natasha Barrow

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Data Finds Capillary Blood Is A Reliable Alternative To Venous Blood For Routine Testing

 
• By Natasha Barrow

A study from Babson Diagnostics published in the peer-reviewed Journal of Applied Laboratory Medicine showed that capillary blood sample volume issues can overcome historical challenges, such as poor quality, through a technique called assay miniaturization.

Inclusive By Design: UK Invites Sponsors To Submit Trial Diversity Plans

 
• By Vibha Sharma

The UK has issued clearer guidance to help drug and medical device sponsors demonstrate how they intend to include a diverse and relevant range of participants in their clinical trials.

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

More from R&D

First Alzheimer’s Disease Diagnostic Blood Test Cleared By FDA

 
• By Natasha Barrow

Fujirebio Diagnostics' Alzheimer's disease test, Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, has been cleared by the US FDA.

Mirvie Launches Predictive Blood Test For Preeclampsia

 
• By Marion Webb

Mirvie launched Encompass, a blood test to help identify women over age 35 who are at moderate risk for preeclampsia, and will conduct additional studies to support reimbursements from payers.

SpotitEarly Raised $20.3M In New Funding To Bring AI- And Dog-Sniffing-Powered Early Cancer Detection Test To US

 
• By Marion Webb

Israeli-based SpotitEarly hopes to bring an early cancer-detection test, which uses dogs’ noses to detect compounds in exhaled breath and AI analysis, to US homes in 2026.